NCT03183726View on ClinicalTrials.gov

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial

CompletedOBSERVATIONAL
Enrollment

4

Participants

Timeline

Start Date

January 11, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

July 31, 2017

Conditions
Diabetic Foot Ulcer
Interventions
BIOLOGICAL

ALLO-ASC-DFU

"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.~This study is a follow-up study without intervention."

All Listed Sponsors
lead

Anterogen Co., Ltd.

INDUSTRY

NCT03183726 - A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial | Biotech Hunter | Biotech Hunter